The US Food and Drug Administration has approved a new stand-alone continuous glucose monitoring (CGM) system, Medtronic’s Guardian Connect, that alerts users to impending high and low blood glucose levels up to an hour in advance.
The device is approved for people with diabetes aged 14 to 75 years and targeted at those using multiple daily insulin injections. The Guardian 3 sensor is the same one used in Medtronic’s so-called artificial pancreas, the MiniMed 670G, a hybrid closed-loop CGM system, which accurately alerts patients of 98.5% of hypoglycemic events, according to a company statement.
Guardian Connect does not have a receiver and will be the first CGM to launch in the United States that has smartphone display as the only option for viewing data.
Read more at https://www.medscape.com/viewarticle/893851